PET study shows oxytocin failing to aid serotonin in the autistic brain

The “cuddle hormone” and neurotransmitter oxytocin, which has been shown to improve social skills in individuals with autism spectrum disorders (ASD), does not boost beneficial serotonin activity in these patients as it clearly does in their non-autistic peers, according to a PET-based study conducted at the Institute of Cognitive Sciences in Lyon, France.

While disappointing, the neuroimaging finding may lead to research aimed at better understanding the oxytocin-serotonin connection.

The study was published online Oct. 17 in Cerebral Cortex.

Lead author Arthur Lefevre, PhD, senior author Angela Sirigu, PhD, and colleagues mapped the effects of nasally inhaled oxytocin on serotonin in 18 patients with ASD and 24 healthy controls.

All participants underwent one PET scan with the oxytocin nasal spray and one scan without (for baseline).

The researchers used the radiotracer 18F-MPPF to mark the serotonin 1A receptor (serotonin-1AR) and measured the binding potential of the tracer.

This measurement provided an indication of how well the oxytocin had modulated the receptor.

The team found that, at baseline, the ASD patients did not differ from controls for serotonin-1AR concentration and distribution.

However, the oxytocin significantly increased MPPF binding potential in several brain regions of the healthy controls—but did not change the binding potential at all in the ASD group.

Serotonin serum concentration analysis corroborated these results, the authors report.

“Our findings suggest a disturbed oxytocin-serotonin interaction in autism,” they write. “This may limit the potential benefits of oxytocin in these patients and open the ways to investigate combined oxytocin-serotonin treatments.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

Trimed Popup
Trimed Popup